Literature DB >> 26209907

The role of infectious diseases in the catastrophic antiphospholipid syndrome.

M Garcia-Carrasco1, C Mendoza-Pinto1, S Macias-Diaz2, F Vazquez de Lara3, I Etchegaray-Morales2, J L Galvez-Romero4, S Mendez-Martinez5, R Cervera6.   

Abstract

Catastrophic antiphospholipid syndrome (CAPS), also called "Asherson syndrome", is a variant of the antiphospholipid syndrome (APS) that occurs in less than 1% of APS cases. The etiology of CAPS is uncertain; however, several triggering factors have been recognized. The most common of these are infectious diseases, particularly those of the respiratory tract. CAPS pathogenesis is incompletely understood, but several theories have been proposed, such as the molecular mimicry theory, which describes the production of anti-β2-glycoprotein I (GP1) antibody in response to infection. The process is complex and involves the activation of Toll-like receptor 4 (TLR-4), which triggers a cytokine storm, followed by endothelial alterations that induce a procoagulant state.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antibiotic; Asherson syndrome; Catastrophic antiphospholipid syndrome; Cytokine storm; Infection; Molecular mimicry; Toll-like receptor 4; β2-glycoprotein I

Mesh:

Substances:

Year:  2015        PMID: 26209907     DOI: 10.1016/j.autrev.2015.07.009

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  11 in total

1.  Catastrophic antiphospholipid syndrome: A case with unusual findings revealed in autopsy and a brief literature update.

Authors:  Flavio Signorelli; Gustavo Guimarães Moreira Balbi; Roger A Levy
Journal:  Eur J Rheumatol       Date:  2017-10-25

2.  Pediatric APS: State of the Art.

Authors:  Arzu Soybilgic; Tadej Avcin
Journal:  Curr Rheumatol Rep       Date:  2020-03-03       Impact factor: 4.592

Review 3.  Probable Catastrophic Antiphospholipid Syndrome with Intracerebral Hemorrhage Secondary to Epstein-Barr Viral Infection.

Authors:  Mark P Plummer; Adam M H Young; Ronan O'Leary; Maxwell S Damian; Andrea Lavinio
Journal:  Neurocrit Care       Date:  2018-02       Impact factor: 3.210

Review 4.  Lymphocyte Disturbances in Primary Antiphospholipid Syndrome and Application to Venous Thromboembolism Follow-Up.

Authors:  Laurent Simonin; Elisabeth Pasquier; Christophe Leroyer; Divi Cornec; Julie Lemerle; Boutahar Bendaoud; Sophie Hillion; Jacques-Olivier Pers; Francis Couturaud; Yves Renaudineau
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

5.  Anticardiolipin from Periodontitis Patients Impact Fetal Loss and Annexin V.

Authors:  H A Schenkein; R R Thomas
Journal:  J Dent Res       Date:  2020-03-23       Impact factor: 6.116

Review 6.  Anti-phospholipid Antibodies and Smoking: An Overview.

Authors:  Steven R Binder; Christine M Litwin
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

Review 7.  Entangling COVID-19 associated thrombosis into a secondary antiphospholipid antibody syndrome: Diagnostic and therapeutic perspectives (Review).

Authors:  Eugenio Cavalli; Alessia Bramanti; Rosella Ciurleo; Andrey I Tchorbanov; Antonio Giordano; Paolo Fagone; Cristina Belizna; Placido Bramanti; Yehuda Shoenfeld; Ferdinando Nicoletti
Journal:  Int J Mol Med       Date:  2020-06-25       Impact factor: 4.101

Review 8.  COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome?

Authors:  Serena Colafrancesco; Cristiano Alessandri; Fabrizio Conti; Roberta Priori
Journal:  Autoimmun Rev       Date:  2020-05-05       Impact factor: 9.754

9.  Catastrophic Antiphospholipid Syndrome after Orthotopic Liver Transplant.

Authors:  R Okeke; J Lok; R Wells; M Wycoff; A Engelhardt; J Bettag; C O'Leary; T Hallcox; M Nazzal
Journal:  Case Rep Transplant       Date:  2022-05-05

Review 10.  Untangling the Intricacies of Infection, Thrombosis, Vaccination, and Antiphospholipid Antibodies for COVID-19.

Authors:  Nevio Cimolai
Journal:  SN Compr Clin Med       Date:  2021-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.